By Joe Hoppe
Evgen Pharma PLC said Monday that it has made further progress on its SFX-01 drug candidate, indicating it might help metastatic breast cancer patients, and outlined further plans to test it on glioblastoma brain tumors.
The U.K. pharmaceutical company said that the University of Manchester is investigating the effectiveness of SFX-01 in metastatic breast cancer patients with a resistance to DCDK4/6 inhibitors, the first line metastatic breast cancer treatment for patients who are estrogen receptor positive.
Tumors appeared to shrink and 24% of late-stage patients showed a durable clinical benefit for at least six months. In-vitro preclinical work is underway, and if successful the company said it will pursue a Phase 2 placebo-controlled study, which could begin in 2022.
The company also said that it has successfully reproduced data published Jan. 21 finding SFX-01 reduces glioblastoma brain tumor cells in-vitro, but using freshly extracted cells from patients rather than standard glioblastoma cell lines. Further in-vivo work has begun to build upon the experiments. Plans for a Phase 2 clinical trial are progressing with a scheduled start for the first half of 2022.
Glioma is the most common form of brain tumor, affecting 1 in 20,000 people, while glioblastoma --the more severe classification-- represents 45% of all cases.
Write to Joe Hoppe at joseph.hoppe@wsj.com
"breast" - Google News
June 14, 2021 at 01:54PM
https://ift.tt/3gjsSl6
Evgen Pharma Says SFX-01 Drug Making Progress in Breast, Brain Cancer Tests - MarketWatch
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "Evgen Pharma Says SFX-01 Drug Making Progress in Breast, Brain Cancer Tests - MarketWatch"
Post a Comment